The Þ rst method employing simultaneous equation is a very simple method and can be employed for routine analysis of these two drugs in combined dosage form using simple instrumentation. Once the molar absorptions are determined, very little time will be required for routine analysis, as it would only require determination of absorbance of sample at the two selected wavelengths and few simple calculations.
The second method employed the graphic absorbance ratio at two selected wavelength, once the absorbance is determined. The reported methods were found to be accurate, simple and rapid. Hence it can be employed for routine analysis of both drugs in quality control laboratories. To determine the content of the drug in solid dosage form, 20 tablets were accurately weighed, their average weight calculated and they were finely powdered. Powder equivalent to 40 mg of the drug was dissolved in methanol and sonicated for 20 min. The solution was Þ ltered and diluted to 100 ml with the same solvent. An aliquot measuring 1 ml was diluted to 10 ml with methanol and this solution was appropriately applied on the plate to get approximately 400 ng/spot of the drug. The results obtained are summarized in Table 1 . The method was validated as per ICH guidelines 17 .
A standard stock solution of the drug was applied on the plate so as to contain 200-2000 ng of propranolol hydrochloride per spot. The plate was developed, dried, and scanned as described above. All measurements were repeated 6 times for each concentration. Correlation coefÞ cient (r) of the line, passing through all the points on a graph constructed by plotting mean of peak areas on ordinate against corresponding concentrations on ordinate, was found to be 0.9997 with slope 4.905.
Limit of detection (LOD) and limit of quantitation (LOQ) were studied to determine the sensitivity of the Propranolol hydrochloride, chemically 1-[(1-m e t h y l e t h y l ) a m i n o ] -3 -( 1 -n a p h t h y l e n y l o x y ) -2-propranolol hydrochloride 1 , is a non-selective β-adrenergic antagonist. It is used in the management of hypertension, phaeochromocytoma, angina pectoris, myocardial infarction and cardiac arrhythmias 2 . Literature reported several titrimetric 3 , complexation 4 and spectrometric 5 methods for analyzing propranolol. Several HPLC methods have also been reported for determining propranolol in pharmaceutical formulations and in biological fluids [6] [7] [8] [9] [10] [11] [12] [13] [14] . Indian Pharmacopoeia describes a spectrometric method 15 , whereas, USP describes a HPLC method 16 for assaying the drug. Following description is of a rapid, reliable and accurate HPTLC method for determination of propranolol hydrochloride in tablets.
All chemicals used were of analytical reagent grade, purchased from M/s Qualigens Fine Chemicals Ltd., Mumbai, India. The tablets were procured from the local market. HPTLC system consisted of Camag Linomat V applicator (Muttenz, Switzerland), a Camag twin trough TLC chamber of appropriate size, Camag TLC scanner 3, Wincats software (version 1.3.0.) and a Hamilton syringe (Switzerland) of 100 µl capacity.
Chromatography was performed on 20×10 cm aluminium backed silica gel 60 F 254 TLC plates (Merck, Darmstadt, Germany). Samples, applied as solutions of appropriate concentrations using Hamilton micro syringe and Linomat V applicator (Camag, Muttenz, Switzerland) were 6 mm wide bands with a distance of 13 mm within each spot. The plate was developed by ascending movement of solvent system, for 70 mm from the point of application, in a Camag twin trough chamber which was previously saturated with vapors of solvent system for a pre-optimized time period of 20 min at 25°±2°. The solvent system consisted of isopropanol:ethyl acetate:ammonia (1:8.5:0.5 v/v/v). The plate was dried and scanned at 290 nm, using Camag TLC scanner 3, equipped with Wincats software version 1.3.0., and slit dimensions of the scanner being set at 6.00 × 0.45 mm. Table 4 . The optimized solvent system yielded a symmetrical peak for the drug with R f 0.52 ( fig. 1) . A typical absorbance spectrum of the drug is shown in Þ g. 2. The peak for the drug from tablets was identiÞ ed by comparing the R f, and also comparing its absorbance spectrum with that obtained with the standard drug. Peak purity was determined by co-relating the spectra of drug at peak start (s), peak apex (m) and at peak end (e) positions, (correlation r (s, m) = 0.9999, r (m, e) = 0.9997). Thus, it can be concluded that no impurities or degradation products, likely to be present in the marketed tablets, were found to interfere with the peak of the drug.
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To ensure accuracy of the method, recovery studies were performed by standard addition method at 80%, 100% and 120% level, to the pre-analyzed samples and the subsequent solutions were re-analyzed. At each level, three determinations were performed and the results obtained are shown in Table 2 . The results of recovery studies were within the speciÞ ed limits of ICH guidelines. Lower values of % RSD reß ect the accuracy of the method.
Precision, expressed in terms of % RSD, was determined in terms of intra-day and Inter-day precisions, analyzing the drug at three different concentrations, determining each concentration thrice. The sample solutions were analyzed using the method for 3 consecutive days, repeating the process twicea-day at different period. The results obtained are summarized in Table 3 , and reflect high degree of precision.
Two different analyst performed assay on marketed tablets of the drug, in similar operational and environmental conditions, using the developed method to determine its ruggedness, and the results are 
